CK Life Sciences Int'l. (Holdings) Inc. filed its monthly return for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month. The filing was submitted to Hong Kong Exchanges and Clearing Limited on 02 June 2026.

The company’s authorised share capital stood at 15.00 billion ordinary shares with a par value of HKD 0.10 each, equivalent to HKD 1.50 billion.

Issued share capital was steady at 9.61 billion ordinary shares, and the issuer held no treasury shares. Consequently, the total number of issued shares (excluding treasury shares) also remained at 9.61 billion.

CK Life Sciences confirmed that it continued to meet the Main Board’s minimum public-float requirement of 25 percent as of 31 May 2026.

The company reported no activity under share option schemes, warrants, convertible instruments, or other agreements that could result in future share issuances during the month.